NDA/PLA CLASS OF FY 1995 WILL ACHIEVE APPROVAL RATE OF APPROXIMATELY 80% -- USER FEE REPORT; CBER PILOTING "COMPLETE REVIEW" LETTERS TO REPLACE "APPROVABLE"
FDA expects that about 80% of the 118 NDAs and PLAs submitted in fiscal 1995 will ultimately be approved, the agency estimates in a user fee performance report forwarded to Congress on Dec. 6.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth